Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer [0.03%]
转移性去势抵抗性前列腺癌患者的治疗优化
Pierre-Yves Cren,James Buteau,Umma Fatema et al.
Pierre-Yves Cren et al.
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved substantially over the past decade, with androgen receptor pathway inhibitors, taxanes, poly (ADP-ribose) polymerase (PARP) inhibitors, radiois...
Right-Sizing Locoregional Management in the Era of Neoadjuvant Therapy for Breast Cancer [0.03%]
新辅助治疗时代的乳腺癌局部区域治疗的优化选择
Stephanie M Wong,Corey Speers,Mark V Schaverien
Stephanie M Wong
The increasing use of neoadjuvant systemic therapy (NAC) has led to a significant paradigm shift in the locoregional treatment of breast cancer, with increasing emphasis on response-guided de-escalation. In current practice, both clinical a...
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations [0.03%]
精准免疫治疗：以靶向创新手段变革癌症治疗
Myung-Ju Ahn,Bernadett Szabados,Will Ince et al.
Myung-Ju Ahn et al.
While immune checkpoint inhibitors have transformed treatment for many cancers, their benefit remains limited across all tumor types and is constrained by immune-related toxicity. Targeted immunotherapies, including T-cell engagers (TCEs), ...
Tobias Tix,Anita Kumar,Toby A Eyre et al.
Tobias Tix et al.
Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell malignancy with variable prognosis, ranging from indolent, asymptomatic forms to aggressive subtypes with early treatment failure. Contemporary management emph...
Promising New Platforms and Targets in the Management of Gastroesophageal Cancers [0.03%]
胃食管肿瘤管理中新平台和新靶点的展望
Jeesun Yoon,Caroline Y Chen,Robert Watson et al.
Jeesun Yoon et al.
Gastric and gastroesophageal junction cancers remain a major global cause of cancer-related mortality. Despite incremental advances in surgery and systemic therapy, durable survival gains have been limited, underscoring persistent unmet med...
Beyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management [0.03%]
超越常规监测成像的黑色素瘤检测新技术：早期复发检测及临床治疗指导方法
Giselle de Souza Carvalho,Cicero Luiz Cunha de Sousa Martins,Kevin Wang et al.
Giselle de Souza Carvalho et al.
Melanoma recurrence risk is highest within the first 2 years after diagnosis and progressively declines thereafter. Current surveillance strategies remain largely guided by clinicopathologic risk stratification, with the comprehensive medic...
Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions [0.03%]
局部结直肠癌的免疫治疗：当前实践与未来方向
Evelyn Yi Ting Wong,Sheela R Damle,Kai-Keen Shiu et al.
Evelyn Yi Ting Wong et al.
Immune checkpoint inhibitors (ICIs) have fundamentally transformed the treatment landscape for localized colorectal cancer (CRC), particularly for the mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) subgroups. Th...
Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter [0.03%]
创新、证据、同理心和希望：创造有意义的价值
Samuel X Stevens,Michelle Leah Tregear,Rachel Riechelmann et al.
Samuel X Stevens et al.
Over the past 50 years, advances in systemic therapy, radiotherapy, surgery, and supportive care have dramatically improved cancer outcomes. Yet, growing concern exists that in our race for biomedical innovation, the metrics used to evaluat...
Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems [0.03%]
DPYD检测在医疗系统中预防严重氟尿嘧啶类化疗毒性的实施策略和重要性
Jeremy Kratz,Karen Merritt,Jessica Jorgensen et al.
Jeremy Kratz et al.
Recent regulatory and guideline changes have established pretreatment DPYD genotyping as a critical strategy to prevent severe fluoropyrimidine toxicity. Following earlier European leadership by the European Medicines Agency, the US Food an...
Harnessing Artificial Intelligence for the Management of Patients With GI Cancers [0.03%]
人工智能在消化系统癌症患者管理中的应用
Lipika Goyal,Caroline Chung,Yuichi Mori et al.
Lipika Goyal et al.
Artificial intelligence (AI) has the potential of reshaping GI oncology by enabling more nuanced interpretation of complex clinical, imaging, and molecular data, while supporting more timely and patient-centered decisions. This article synt...